Table 5.

Individual baseline characteristics and outcome of subjects with newly diagnosed AML (de novo or secondary to MDS), unfit for standard therapy

BST-236 dose, g/m2 per d	No. of induction courses	Age, y	ECOG PS	Prior MDS	No. of prior HMA courses	ELN cytogenetic risk score	Molecular aberration	Cytogenetics	Baseline BM blasts, %	Baseline PB blasts, %	Baseline WBC, ×109/L	Best response	Survival, d
0.8	2	80	1	No	0	Adverse	FLT3+, NPM1+	NK	80	13	7.06	CRp	308
1.5	1	76	0	Yes	0	Intermediate	IDH1+, NMP1+	NK	81	24	7.26	Withdrawn*	36
1.5	1	80	0	Yes	26	Adverse	None	5q− (+ complex karyotype)	36	0	0.75	Refractory	13
2.3	1	83	2	Yes	0	Intermediate	None	NK	90	ND	0.75	PR	79
2.3	1	73	0	Yes	5	Intermediate	None	NK	58	53	2.41	Refractory	18
2.3	1	78	0	No	0	Adverse	FLT3+	NK	43	30	2.50	Refractory	28
2.3	1	70	1	Yes	5	Intermediate	None	NK	22	9	1.86	CR	623
4.5	1	72	1	Yes	0	Adverse	FLT3+, NPM1+	NK	85	ND	11.00	Refractory	207
4.5	1	77	2	Yes	10	Adverse	None	Del 7	30	ND	4.30	CR	397
6	1	88	1	Yes	9	Favorable	NPM1+	NK	100	85	61.82	Refractory	88
6	2	81	1	No	0	Adverse	None	Complex karyotype	100	40	24.55	CR	195

ND, not done; NK, normal karyotype; PB, peripheral blood; PR, partial response; WBC, white blood cells.

^*Withdrawn on day 2 due to pneumonia.